**DATA ACCESS AGREEMENT**

**These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions.**

**Definitions**

***Authorised Personnel****:* The individuals at the User Institution to whom The InsPIRE consortium grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II.

***Data****:* The managed access datasets to which the User Institution has requested access.

***Data Producers****: Members of the InsPIRE consortium* and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data.

***External Collaborator****:* A collaborator of the User, working for an institution other than the User Institution.

***Project****:* The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II.

***Publications****:* Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research.

***Research Participant****:* An individual whose data form part of these Data.

***Research Purposes***: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research.

***User****:* The principal investigator for the Project.

***User Institution(s)****:* TheInstitution that has requested access to the Data.

***XXXXX****:* Your Institution details here

1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I.

2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data.

3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification.

4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction.

5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data.

6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data.

7. The User Institution agrees to follow the *Fort Lauderdale Guidelines* ([*http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy\_communications/documents/web\_document/wtd003207.pdf*](http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf)) and the *Toronto Statement* ([*http://www.nature.com/nature/journal/v461/n7261/full/461168a.html*](http://www.nature.com/nature/journal/v461/n7261/full/461168a.html)). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgementin all reports or publications resulting from the use of theseData.

8. The User Institution agrees to follow the *Publication Policy* in Appendix III. This includes respecting themoratorium period for the Data Producers to publish the first peer-reviewed report describing andanalysing these Data.

9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data.

10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health *Best Practices for the Licensing of* *Genomic Inventions (2005)* (*https://www.icgc.org/files/daco/NIH\_BestPracticesLicensingGenomicInventions\_2005\_en.pdf* )in conformity with the Organisation for Economic Co-operation and Development *Guidelines for the Licensing of the Genetic Inventions (2006)* (*http://www.oecd.org/science/biotech/36198812.pdf* ).

11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements.

12. The User Institution will notify members of the InsPIRE steering committee (acting on behalf of InsPIRE collaborators) within 30 days of any changes or departures of Authorised Personnel.

13. The User Institution will notify InsPIRE steering committee (acting on behalf of InsPIRE collaborators) prior to any significant changes to the protocol for the Project.

14. The User Institution will notify InsPIRE steering committee (acting on behalf of InsPIRE collaborators) as soon as it becomes aware of a breach of the terms or conditions of this agreement.

15. InsPIRE steering committee may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements.

16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement.

17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement.

18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement.

**Agreed for User Institution**

|  |  |
| --- | --- |
| **Signature:** |  |
| **Name:** |  |
| **Title:** |  |
| **Date:** |  |

**Principal Investigator**

**I confirm that I have read and understood this Agreement.**

|  |  |
| --- | --- |
| **Signature:** |  |
| **Name:** |  |
| **Title:** |  |
| **Date:** |  |

**Agreed for InsPIRE steering committee (acting on behalf of InsPIRE collaborators)**

|  |  |
| --- | --- |
| **Signature:** |  |
| **Name:** |  |
| **Title:** |  |
| **Date:** |  |

**APPENDIX I – DATASET DETAILS**

**APPENDIX II ––PROJECT DETAILS**

**APPENDIX III –– PUBLICATION POLICY**

**APPENDIX I *–* DATASET DETAILS (to be completed by the data producer before passing to applicant)**

**Dataset reference (EGA Study ID and Dataset Details)**

EGAS00001003997 dataset which includes RNAseq samples form pancreatic islets produced in the institutions named: Oxford (including samples from Oxford University and Edmonton University), USA (including samples from NIH) and Geneva (including samples produced in Geneva University). The same dataset includes RNAseq samples from beta-cells and genotypes for all individuals in the study.

**Name of project that created the dataset**

InsPIRE consortium (Integrated Network for Systematic analysis of Pancreatic Islet RNA Expression).

**Names of InsPIRE steering committee members:**

* Michael R. Erdos. Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA.
* Anna L. Gloyn. Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
* Emmanouil T. Dermitzakis. Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
* Alvin C. Powers. Vanderbilt University Medical Center. Vanderbilt Diabetes Center, Department of Medicine, and Department of Molecular Physiology and Biophysics. Nashville, USA.

**Names of other data producers/collaborators**

Ana Viñuela1,2,3#,\*, Arushi Varshney4#, Martijn van de Bunt5,6,7#,$, Rashmi B Prasad8,#, Olof Asplund8, Amanda Bennett5, Michael Boehnke9, Andrew A. Brown1,2,3, Michael R Erdos10, João Fadista8,12, Ola Hansson8, Gad Hatem8, Cédric Howald1,2,3, Apoorva K. Iyengar12, Paul Johnson5, Ulrika Krus8, Patrick E. MacDonald13, Anubha Mahajan5, Jocelyn E. Manning Fox13, Narisu Narisu10, Vibe Nylander6, Peter Orchard14, Nikolay Oskolkov8, Nikolaos I. Panousis1,2,3, Anthony Payne5, Michael L Stitzel15,16, Swarooparani Vadlamudi12,Ryan Welch9, Francis S. Collins10, Karen L. Mohlke12, Anna L. Gloyn5,6,7, Laura J. Scott9, Emmanouil T. Dermitzakis1,2,3, Leif Groop8,17, Stephen C.J. Parker4,14, Mark I. McCarthy5,6,7,\*.

1) Department of Genetic Medicine and Development, University of Geneva Medical School, 1211 Geneva, Switzerland. 2) Institute for Genetics and Genomics in Geneva (iGE3), University of Geneva, 1211 Geneva, Switzerland. 3) Swiss Institute of Bioinformatics, 1211 Geneva, Switzerland. 4) Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109. 5) Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7BN, UK. 6) Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK. 7)Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, OX3 7LE, UK. 8) Lund University Diabetes Centre, Department of Clinical Sciences, Lund University,Skåne University Hospital, Malmö, Sweden. 9) Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48109. 10) Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, 20892, USA. 11) Department of Epidemiology Research, Statens Serum Institut, Copenhagen, DK-2300, Denmark. 12) Department of Genetics, University of North Carolina, Chapel Hill, NC 27599. 13) Department of Pharmacology and Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada. 14) Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI 48109. 15) The Jackson Laboratory for Genomic Medicine, Farmington, CT 06032. 16) Department of Genetics and Genome Sciences, Institute for Systems Genomics, University of Connecticut, Farmington, CT 06032. 17) Finnish Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland.

**Specific limitations on areas of research**

In support of points 2 and 3 of this agreement, no research aimed to develop or evaluate methodology to identify the anonymous donors can be perform with this data.

**Minimum protection measures required**

***File access:*** *Data can be held in unencrypted files on an institutional compute system, with Unix user group read/write access for one or more appropriate groups but not Unix world read/write access behind a secure firewall. Laptops holding these data should have password protected logins and screenlocks (set to lock after 5 min of inactivity). If held on USB keys or other portable hard drives, the data must be encrypted.*

**APPENDIX II *–* PROJECT DETAILS (to be completed by the Requestor)**

**Details of dataset requested i.e., EGA Study and Dataset Accession Number**

**Brief abstract of the Project in which the Data will be used (500 words max)**

**All Individuals who the User Institution to be named as registered users**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Name of Registered User*** | ***Email*** | ***Job Title*** | ***Supervisor\**** |
|  |  |  |  |
|  |  |  |  |

**All Individuals that should have an account created at the EGA**

|  |  |  |
| --- | --- | --- |
| **Name of Registered User** | **Email** | **Job Title** |
|  |  |  |
|  |  |  |

**APPENDIX III *–* PUBLICATION POLICY**

XXXXX intend to publish the results of their analysis of this dataset and do not consider its deposition into public databases to be the equivalent of such publications. XXXXX anticipate that the dataset could be useful to other qualified researchers for a variety of purposes.

In any publications based on these data, please describe how the data can be accessed, including the name of the hosting database (e.g., The European Genome-phenome Archive at the European Bioinformatics Institute) and its accession numbers (e.g., EGAS00000000029), and acknowledge its use in a form agreed by the User Institution with the InsPIRE consortium.